Patients may require life-long monitoring and a collaborative engagement with subspecialists to keep well in the long -term,” ...

In the initial publication in 2021, the KETYNOTE-564 trial demonstrated that adjuvant pembrolizumab was associated with significantly longer disease-free survival than placebo (24 months: 77% vs. 68%; ...

has a chance to draw level again with Merck & Co's rival cancer immunotherapy Keytruda (pembrolizumab), which was approved for adjuvant treatment of melanoma last December. Securing approvals in ...

Opdualag – which combines the PD-1 inhibitor nivolumab in BMS' blockbuster cancer drug Opdivo with LAG-3 inhibitor relatlimab ...

Major pathologic response serves as a key factor in determining subsequent adjuvant ... compared with pembrolizumab monotherapy in patients with high-risk, resected stage III melanoma while ...

This page is about targeted cancer drugs and immunotherapy for melanoma ... pembrolizumab (Keytruda). A nurse gives it to you as a drip into your blood stream (intravenously). It helps reduce the risk ...

The failure in adjuvant melanoma could cause BMS and Opdualag to miss out on a market opportunity that is nearly twice as ...

Upon Opdualag’s approval in 2022 as a first-in-class cancer immunotherapy, Bristol Myers Squibb was anxious to explore its potential in a variety of indications. | Bristol Myers Squibb is striking out ...

A Bristol Myers Squibb immunotherapy currently approved as a first-line treatment for metastatic melanoma has failed a pivotal clinical trial intended to support expanding the therapy’s use to ...

A phase 1 study of a personalized cancer vaccine demonstrated antitumor immunity in all treated patients with resected renal ...

Nivolumab with ipilimumab for adjuvant treatment of localised renal cell carcinoma TS [ID9659] Technology appraisal guidance Nivolumab–relatlimab for adjuvant treatment of resected stage 3 or 4 ...